CompletedNCT06236880
GM-2505 safety study for major depression
About this title
Read the official source — NCT06236880This study evaluated the safety of GM-2505 for people with depression.
Medication studyAges 18–65United Kingdom
Understand this study
What did researchers investigate?
This study evaluated the safety of GM-2505 for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- ManchesterSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: January 31, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 126
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06236880
- Official title
Show the full official title
A Phase 2a Study to Evaluate the Safety and Tolerability of Two Repeated Doses of GM-2505 at a 2-Week Interval in Patients With Major Depressive Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Manchester
Questions about this study
What did researchers investigate?
This study evaluated the safety of GM-2505 for people with depression.
Who is behind this study?
The study sponsor is AbbVie.
Did this study involve medication?
Yes. The study involved medication, including GM-2505.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
